Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health,
Taxation and Finance
|
Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
|
Policies or Program
|
Health,
Labour
|
Communicating with government officials about federal healthcare plans and benefits.
|
Policies or Program
|
Health
|
Communicating with government officials about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
|
Policies or Program
|
Health,
Intellectual Property
|
Communicating with government officials about regulations related to patented medicines, including the "Patented Medicines (Notice of Compliance) Regulations" (SOR/93-133) under the Patent Act.
|
Regulation
|
Health,
Intellectual Property
|
Communicating with government officials about regulations, guidelines, reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
|
Policies or Program
|
Health
|
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution
|
Science and Technology
|
Communicating with government officials about the Government of Canada's "Biomanufacturing and Life Sciences Strategy" (2021).
|
Policies or Program
|
Health,
Science and Technology
|
Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.
|
Policies or Program
|
Science and Technology
|
Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communicating with government officials about the Pan-Canadian Health Data Strategy, more specifically about health data foundations.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Establishment of Canadian Drug Agency and National Formulary
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal Life Sciences/ Biomanufacturing Strategy
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act Modernization initiative, as it relates to reform of drug submission review and approval process.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Industry Canada Advantage Canada and Science and Technology Strategies, or other Government policy or program initiatives to support research and development activities in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
National Pharmaceutical Strategy, as it relates to enhanced access to orphan drugs and incentives for development of the treatments for rare disorders.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property and approval for therapeutic products.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB), as it relates to implementation timeframe, pricing, guidelines, reporting requirements and dispute resolution.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB), as it relates to pricing guidelines.
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-04-30 |
|
Health |
2024-04-30 |
|
Health |
2024-04-30 |
|
Health |
2024-04-29 |
|
Health |
2024-03-05 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |
2024-02-29 |
|
Health |